ST Pharm
ST Pharm
01
Who we are
02
Our record
03
Newsroom
04
Contact
En
Ko
ST Pharm
Science & Technology
Business Overview
사업영역
CDMO
위탁생산개발
Small Molecule
Oligonucleotide
mRNA
CRO
위탁임상서비스
AnaPath Research & Service
R&D
연구개발
Virtual R&D
Global R&D
About
ST PHARM
핵심인력
연혁
Global 인증
자회사
Public
PR (Public Relations)
News room
All
Media Focus
ST PHARM News
IR (Investor Relations)
Stock Information
IR Library
Disclosure Information
IR Materials
Notice
Careers
ESG
Overview
Environmental
Social
Governance
Sitemap
Contact
Linkedin
Public
IR Materials
PR (Public Relations)
News room
All
Media Focus
ST PHARM News
IR (Investor Relations)
Stock Information
IR Library
Disclosure Information
IR Materials
Notice
IR Materials
Aug 17, 2022
[IR 자료] 대신증권 NDR용 IR자료입니다.
[업데이트 내용]
- 유전자치료제(Gene Therapy) 범주
- Alnylam의 자체 siRNA 신약 개발 성공율 62.5%
- NAI 등급의 FDA cGMP 인증 등
「반출」에스티팜_IR (2022.08)_20220816.pdf
List